Fw: Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells

[Guest guest]

From: AIDSmeds <news@...>Date: Wed, 14 Mar 2012 09:31:25 -0400<nelsonvergel@...>Subject: Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells Conference Coverage19th Conference on Retroviruses andOpportunistic InfectionsAIDSmeds continuesits coverage from one of the most important annual HIV/AIDSresearch meetings: The 19th Conference on Retroviruses andOpportunistic Infections (CROI 2011). We are adding newarticles to our CROI2011 conference page at a steady clip—keepchecking in over the next few weeks as our coveragecontinues.CROI 2012 NewsMarch 13, 2012BlackWomen Twice as Likely to Die of AIDS in U.S. Compared toWhite HIV-Positive Women Some sobering news from the Women’sInteragency HIV Study (WIHS): Black women living with HIVare more likely to progress to AIDS and twice as likely todie of its complications compared with white women livingwith HIV, according to new results from thecohort.‘Quad’Comparable to Norvir-Reyataz Regimen in Phase III StudyA study of Gilead Sciences’“Quad” fixed-dose combination tablet containingthe experimental integrase inhibitor elvitegravir andboosting agent cobicistat, along with tenofovir andemtricitabine, has met its primaryobjective—“non-inferiority” compared withthe popular protease inhibitorbased regimen of Norvir(ritonavir)-boosted Reyataz (atazanavir) plus Truvada(tenofovir and emtricitabine).HighBlood Pressure Increases Heart Attack Risk in HIV Elevated blood pressure—includinglevels that don’t yet meet the definition ofhypertension—is associated with a “substantiallygreater” risk of a heart attack among people livingwith HIV, compared with HIV-negative controls, according toa Veterans Health Administration study.March 12, 2012HIVSpeeds Lung Function Decline in Cohort of Smokers HIV is an independent risk factor for lungdisease, according to new data reported Wednesday, March 7,at the 19th Conference on Retroviruses and OpportunisticInfections.ZostavaxShingles Vaccine Generally Safe, Increases Antibody Levels,in People With Stable HIV Two doses of Zostavax, a vaccine againstshingles (herpes zoster), administered six weeks apart is“generally safe” for people living with HIV withCD4 counts of 200 or higher and undetectable viral loads,according to study results.AIDSmeds Exclusive More CROI 2012 NewsMarch 09, 2012Pathwayto a Cure: Cancer Drug Helps Purge HIV From RestingCells Researchers have shown for the first timethat it is possible to target and interrupt the mechanism bywhich HIV remains hidden and unreachable by antiretroviral(ARV) drugs. ADVERTISEMENT:Pathwayto a Cure: Positive Results Continue for Sangamo’sCCR5 Gene Therapy Genetically modifying CD4 cells to knock outthe CCR5 coreceptor resulted in significant CD4 count gainsand notable viral load reductions while off antiretroviral(ARV) therapy.DiabetesDrug Metformin Prevents Worsening of Calcium Deposits inArteries Treatment with the diabetes drug metforminprevented the progression of coronary atherosclerosis(hardening of the arteries) in a study of people living withHIV.March 08, 2012GileadQuad Performance Comparable to Atripla in First-TimeTreatment Takers The first-ever head-to-head study of twoone-pill, once-daily regimens—Gilead Sciences’“Quad” tablet containing the experimentalintegrase inhibitor elvitegravir and boosting agentcobicistat along with tenofovir and emtricitabine, comparedwith Atripla (efavirenz plus emtricitabine andtenofovir)—shows comparable efficacy between the two.CHARTERStudy: Asymptomatic Cognitive Problems 'Harbinger' forFuture Neurologic Decline Numerous studies have noted increasing ratesof neurological disorders in people living with HIV, butmany of the cases included in these findings involvepatients with cognition problems that don’t affectdaily functioning—data often dismissed as beingstatistical artifacts or meaninglessmeasurements.March 07, 2012PoorAdherence Crippled PrEP Efficacy in Women’s StudyIn stark contrast with the encouragingresults from Partners PrEP—a clinical trial of Viread(tenofovir) and Truvada (tenofovir plus emtricitabine)pre-exposure prophylaxis in mixed-status heterosexualcouples—a study focusing specifically on women at riskfor HIV infection found no difference in infection ratesbetween those using daily PrEP and those using placebo.ViiV’sDolutegravir Continues to Show Well After 96 Weeks, VersusSustiva, for First-Time Treatment ViiV Healthcare’s experimentalintegrase inhibitor dolutegravir (S/GSK-572) “comparesfavorably” with efavirenz (found in Sustiva andAtripla), particularly at the selected 50 milligram (mg)dose, with fewer treatment discontinuations due to sideeffects, according to 96-week follow-up data from thecompany’s SPRING-1 clinical trial. 12Weeks of GS-7977 Plus Ribavirin Not Effective for NullResponders With Hep C Genotype 1 Despite rapid reductions in hepatitis Cvirus (HCV) levels in 10 previously treated null responderswith genotype 1 HCV, only one person had a sustainedvirologic response (SVR), or viral cure, aftertreatment with a 12-week, pegylated interferon-freetreatment regimen containing GS-7977 andribavirin. At your request,you are subscribed asnelsonvergel@... to the followingnewsletter(s): AIDSmeds NewsletterPlease remember to add news@... toyour e-mail address book, so that these updates aren'tblocked as spam.To change your subscription information and preferences,please visit lists.smartandstrong.com/?p=preferencesTo stop receiving this newsletter, please visit lists.smartandstrong.com/?p=unsubscribeClick thislink to forward this message to a friend. Did you receive this e-mail from a friend? Please visit lists.smartandstrong.com/?p=subscribe&id=9to signup for your own copy.Copyright 2012 Smart + Strong, 462 Seventh Avenue, 19thFloor, New York, NY 10018. All rights reserved. Terms OfUse and YourPrivacy.powered by phplist v2.10.17, © phpList ltdAt your request,you are subscribed asnelsonvergel@... to the followingnewsletter(s): AIDSmeds NewsletterPlease remember to add news@... toyour e-mail address book, so that these updates aren'tblocked as spam.To change your subscription information and preferences,please visit lists.smartandstrong.com/?p=preferencesTo stop receiving this newsletter, please visit lists.smartandstrong.com/?p=unsubscribeClick thislink to forward this message to a friend. Did you receive this e-mail from a friend? Please visit lists.smartandstrong.com/?p=subscribe&id=9to signup for your own copy.Copyright 2012 Smart + Strong, 462 Seventh Avenue, 19thFloor, New York, NY 10018. All rights reserved. Terms OfUse and YourPrivacy.powered by phplist v2.10.17, © phpList ltd